Mozart Therapeutics presented preclinical data for MTX-101, a novel CD8 Treg network modulator for the treatment of autoimmune disease, at FOCIS 2023 Annual Meeting. The findings suggest that MTX-101 is well-tolerated in humanized mice and selectively acts on CD8 Treg in blood and tissues without activating other immune cells or increasing pro-inflammatory cytokines. MTX-101 possesses a favorable and antibody-like pharmacokinetic profile. Mozart Therapeutics is focused on developing disease-modifying therapies for autoimmune and inflammatory diseases by targeting a novel regulatory CD8 T regulatory cell network.
Mozart Therapeutics has presented preclinical data for their new drug candidate, MTX-101, which targets the treatment of autoimmune diseases. The drug was found to be well-tolerated in humanized mice and selectively acts on CD8 Treg cells without causing activation of other immune cells or an increase in pro-inflammatory cytokines. This is promising news as it suggests that MTX-101 could potentially provide an effective treatment option for individuals suffering from autoimmune disorders. Mozart Therapeutics is committed to developing innovative therapies that target the novel regulatory CD8 T regulatory cell network to treat various autoimmune and